Advancements in artificial intelligence and machine learning are driving transformative tools in drug discovery and biomedical data analysis. Cadence Molecular Sciences launched ROCS X, an AI-enabled platform enabling 3D molecular searches over trillions of compounds to streamline drug candidate identification. Meanwhile, TileDB, Tahoe Therapeutics, and Kepler AI partnered to facilitate large-scale single-cell dataset interrogation using AI agents, improving data accessibility. In medical diagnostics, AI models have enhanced detection of blood-brain barrier permeability, macular degeneration lesions, and breast cancer care delays, illustrating AI’s widespread impact on biosciences and healthcare.